Publications by authors named "A Branchi"
Background: We aimed to evaluate oncological and functional outcomes of index lesion HIFU ablation with Focal-One.
Materials And Methods: We prospectively assessed treatment-naïve men with localized prostate cancer between 2017 and 2019. Inclusion criteria were stage cT ≤ 2, ≥5 years of life expectancy, grade group ≤3.
Management of chronic patients during the COVID-19 pandemic: the experience of a referral center for rare hematological disorders in the hardest-hit region in Italy.
Ann Hematol
August 2021
Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes: Evidence in NAFLD patients and cell cultures.
Biochim Biophys Acta Mol Cell Biol Lipids
December 2019
Article Synopsis
- The study investigates the role of lysosomal acid lipase (LAL), an enzyme important for lipid metabolism, in patients with non-alcoholic fatty liver disease (NAFLD) by measuring its activity in blood samples and liver biopsies.
- Results indicate that LAL activity is significantly lower in NAFLD patients compared to those without fatty liver, and its activity is consistent across different testing methods and unaffected by disease progression.
- In laboratory tests, fatty acid (FA) exposure reduced LAL activity in human liver cells (HepG2), but activating PPAR-alpha receptors effectively restored LAL function, suggesting potential treatments for NAFLD could focus on modulating LAL activity.*
Lysosomal acid lipase (LAL) is responsible for the hydrolysis of cholesteryl esters (CE) and triglycerides (TG) within the lysosomes; generated cholesterol and free fatty acids (FFA) are released in the cytosol where they can regulate their own synthesis and metabolism. When LAL is not active, as in case of genetic mutations, CE and TG accumulate in the lysosomal compartment, while the lack of release of cholesterol and FFA in the cytosol leads to an upregulation of their synthesis. Thus, LAL plays a central role in the intracellular homeostasis of lipids.
View Article and Find Full Text PDFHigh-intensity focused ultrasound (HIFU) treatment has recently been pursued to reduce radical treatment-related morbidity in low-to-intermediate-risk localized prostate cancer (PCa), especially in older men. The aim of this study was to develop a dedicated framework for HIFU therapy. All clinical data, such as risk categories, magnetic resonance with functional parametric imaging, and histopathology, are essential for driving proper HIFU treatment.
View Article and Find Full Text PDF